CIK 0001501989 · Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273521219
- Phone
- 650.515.3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 61 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-02 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award | +60,000 | 332,252 | ||
| 2026-02-02 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2026-02-02 | Ogden Christopher Chief Financial Officer | Grant or award | +90,000 | 316,271 | ||
| 2026-02-02 | Ogden Christopher Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +325,000 | 325,000 | ||
| 2026-02-02 | McCarthy Sean A. CEO | Grant or award | +210,000 | 1,197,891 | ||
| 2026-02-02 | McCarthy Sean A. CEO | Grant or award · Stock Option (Right to Buy) | +980,000 | 980,000 | ||
| 2025-11-06 | McCarthy Sean A. CEO | Option exercise 10b5-1 | +101,793 | $1.59 | $162K | 1,191,477 |
| 2025-11-06 | McCarthy Sean A. CEO | Sale 10b5-1 | −101,793 | $4.54 | $462K | 1,089,684 |
| 2025-11-06 | McCarthy Sean A. CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −101,793 | 348,207 | ||
| 2025-11-06 | McCarthy Sean A. CEO | Sale 10b5-1 | −101,793 | $4.54 | $462K | 987,891 |
| 2025-10-20 | Lester Rachael Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +650,000 | 650,000 | ||
| 2025-09-26 | McCarthy Sean A. CEO | Grant or award · Stock Option (Right to Buy) | +570,000 | 570,000 | ||
| 2025-09-26 | McCarthy Sean A. CEO | Grant or award · Performance Stock Units (PSUs) | +285,000 | 285,000 | ||
| 2025-09-26 | Chu Yu-Waye Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +87,500 | 87,500 | ||
| 2025-09-26 | Chu Yu-Waye Chief Medical Officer | Grant or award · Performance Stock Units (PSUs) | +43,750 | 43,750 | ||
| 2025-09-26 | Ogden Christopher Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +78,250 | 78,250 | ||
| 2025-09-26 | Ogden Christopher Chief Financial Officer | Grant or award · Performance Stock Units (PSUs) | +39,150 | 39,150 | ||
| 2025-09-26 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +36,300 | 36,300 | ||
| 2025-09-26 | BELVIN MARCIA SVP, Chief Scientific Officer | Grant or award · Performance Stock Units (PSUs) | +18,150 | 18,150 | ||
| 2025-06-16 | Ogden Christopher Chief Financial Officer | Sale | −10,614 | $2.69 | $29K | 226,271 |
Page 2 of 27 · 529 trades